<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="189">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01516983</url>
  </required_header>
  <id_info>
    <org_study_id>BD-IC-IV04</org_study_id>
    <nct_id>NCT01516983</nct_id>
  </id_info>
  <brief_title>Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation</brief_title>
  <official_title>A Single Center, Open Label, Dose-Finding Study to Determine the Safety of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Beta Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Beta Pharma Inc.</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of Icotinib at
      different dose levels in combination with whole brain radiotherapy for NSCLC patients with
      brain metastases and EGFR mutation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The long-term control of brain metastases becomes a clinical challenge. Whole brain
      radiotherapy, the standard treatment for patients with multiple brain metastases, can only
      bring a modest survival improvement around 3-6 months. EGFR-TKIs like icotinib with its
      proven activity in non-small cell lung cancer may provide clinical benefits in such
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>6-12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>All cause adverse events (AEs) and serious adverse events (SAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurological progression-free survival</measure>
    <time_frame>3-6 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>All cause neurological progress or mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3-6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>All cause progress or mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6-12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>All cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>3-6 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured by FACT-L/LCS 4.0</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive effects</measure>
    <time_frame>3-6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluated according to Mini-Mental Status Examination</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Icotinib+WBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard whole brain radiotherapy plus icotinib, which is designed to administered at 5 dose according to &quot;3+3&quot; until disease progression or intolerable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>icotinib</intervention_name>
    <description>Level 1: Standard whole brain radiation therapy plus icotinib 125 mg Tid (375 mg per day) from day1 until disease progression or intolerable toxicity.
Level 2: Standard whole brain radiation therapy plus icotinib 250 mg Tid (750 mg per day) from day1 until disease progression or intolerable toxicity.
Level 3: Standard whole brain radiation therapy plus icotinib 375 mg Tid (1125 mg per day) from day1 until disease progression or intolerable toxicity.
Level 4:Standard whole brain radiation therapy plus icotinib 500 mg Tid (1500 mg per day) from day1 until disease progression or intolerable toxicity.
Level 5: Standard whole brain radiation therapy plus icotinib 625 mg Tid (1875 mg per day) from day1 until disease progression or intolerable toxicity.</description>
    <arm_group_label>Icotinib+WBRT</arm_group_label>
    <other_name>BPI-2009, Conmana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Whole brain radiotherapy</intervention_name>
    <description>Whole Brain Radiation Therapy (WBRT) for total dose of 37.5Gy in 15 daily fractions beginning after Day 7.</description>
    <arm_group_label>Icotinib+WBRT</arm_group_label>
    <other_name>RT</other_name>
    <other_name>XRT</other_name>
    <other_name>Radiotherapy</other_name>
    <other_name>WBRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological confirmation of non-small cell lung cancer (NSCLC).

          -  Diagnosis of brain metastases on a Gadolinium-enhanced MRI. More than 3 sites of
             intracranial metastases, or the longest diameter of the intracranial lesion is more
             than 3cm.

          -  Positive EGFR mutation.

        Exclusion Criteria:

          -  Previous usage of EGFR-TKI or antibody to EGFR: gefitinib, erlotinib, herceptin,
             erbitux.

          -  CSF or MRI findings consistent with metastases of spinal cord, meninges or meningeal.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>You Lu</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>You Lu, M.D.</last_name>
    <phone>0086-28-85423571</phone>
    <email>radyoulu@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>You Lu</last_name>
    </contact>
    <investigator>
      <last_name>You Lu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 5, 2013</lastchanged_date>
  <firstreceived_date>January 10, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>EGFR-TKI</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Icotinib</keyword>
  <keyword>WBRT</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
